Peptide therapy targeting the CSPG–PTPσ brake on nerve regrowth
Blocking PTPσ signaling may re-enable intrinsic axon growth after spinal cord injury
After injury, scar tissue rich in CSPGs binds the axonal receptor PTPσ and delivers a stop-growing signal. NVG-291 is a cell-penetrating peptide mimetic that interrupts intracellular relay without removing the receptor, so CSPG can still bind but growth inhibition fails and dormant regrowth programs may resume. If this node is as central to nervous-system repair as GLP-1 agonism was to metabolic disease, successful clinical proof could open a large chronic and acute neuro injury market where no restorative standard of care exists today.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| NGNE | Long | We believe a first-in-class mechanism that releases a hard-wired growth stop after CNS injury addresses an unmet need with very large optionality if randomized data confirm what early human experience suggests; the main risk is binary clinical and regulatory failure while the asset remains investigational. |
Themes
The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.